United Therapeutics Corporation
UTHR
$301.42
-$6.58-2.14%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 19.85% | 23.63% | 25.04% | 23.96% | 26.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 19.85% | 23.63% | 25.04% | 23.96% | 26.09% |
| Cost of Revenue | 18.41% | 20.27% | 24.26% | 37.38% | 56.24% |
| Gross Profit | 20.03% | 24.04% | 25.14% | 22.46% | 23.12% |
| SG&A Expenses | 24.95% | 34.54% | 21.73% | 23.66% | 10.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -126.32% | -- | -- | -- | -- |
| Total Operating Expenses | 22.19% | 25.70% | 29.22% | 33.75% | 24.93% |
| Operating Income | 17.52% | 21.63% | 20.92% | 14.91% | 27.27% |
| Income Before Tax | 13.24% | 20.77% | 24.20% | 25.28% | 47.89% |
| Income Tax Expenses | 6.87% | 18.79% | 26.79% | 34.35% | 60.83% |
| Earnings from Continuing Operations | 15.25% | 21.35% | 23.46% | 22.71% | 44.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.25% | 21.35% | 23.46% | 22.71% | 44.24% |
| EBIT | 17.52% | 21.63% | 20.92% | 14.91% | 27.27% |
| EBITDA | 18.50% | 22.26% | 21.15% | 14.97% | 26.17% |
| EPS Basic | 21.16% | 25.66% | 25.97% | 22.46% | 40.71% |
| Normalized Basic EPS | 27.12% | 31.51% | 34.42% | 26.60% | 39.93% |
| EPS Diluted | 18.50% | 24.01% | 25.37% | 22.99% | 42.31% |
| Normalized Diluted EPS | 24.28% | 29.70% | 33.68% | 27.22% | 41.44% |
| Average Basic Shares Outstanding | -4.90% | -3.42% | -1.56% | 0.43% | 2.62% |
| Average Diluted Shares Outstanding | -2.77% | -2.17% | -1.41% | -0.25% | 1.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |